vs
渤健（BIIB）与TETRA TECH INC（TTEK）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是TETRA TECH INC的1.9倍（$2.3B vs $1.2B），TETRA TECH INC净利率更高（8.7% vs -2.1%，领先10.8%），渤健同比增速更快（-7.1% vs -14.8%），渤健自由现金流更多（$468.0M vs $68.1M），过去两年渤健的营收复合增速更高（-0.2% vs -1.6%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Tetra Tech Inc.是总部位于美国加利福尼亚州帕萨迪纳的咨询与工程服务企业，业务覆盖水资源、生态环境、基础设施、资源管理、能源、国际发展等领域，可提供专业咨询、工程设计、项目管理、施工管理等多元化专业服务。
BIIB vs TTEK — 直观对比
营收规模更大
BIIB
是对方的1.9倍
$1.2B
营收增速更快
BIIB
高出7.6%
-14.8%
净利率更高
TTEK
高出10.8%
-2.1%
自由现金流更多
BIIB
多$399.9M
$68.1M
两年增速更快
BIIB
近两年复合增速
-1.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.2B |
| 净利润 | $-48.9M | $105.2M |
| 毛利率 | 78.3% | 18.2% |
| 营业利润率 | -2.5% | 11.6% |
| 净利率 | -2.1% | 8.7% |
| 营收同比 | -7.1% | -14.8% |
| 净利润同比 | -118.3% | 13424.7% |
| 每股收益（稀释后） | $-0.35 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBTTEK
| Q4 25 | $2.3B | $1.2B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.5B | $1.4B | ||
| Q3 24 | $2.5B | $1.4B | ||
| Q2 24 | $2.5B | $1.3B | ||
| Q1 24 | $2.3B | $1.3B |
净利润BIIBTTEK
| Q4 25 | $-48.9M | $105.2M | ||
| Q3 25 | $466.5M | $127.9M | ||
| Q2 25 | $634.8M | $113.8M | ||
| Q1 25 | $240.5M | $5.4M | ||
| Q4 24 | $266.7M | $778.0K | ||
| Q3 24 | $388.5M | $96.2M | ||
| Q2 24 | $583.6M | $85.8M | ||
| Q1 24 | $393.4M | $76.4M |
毛利率BIIBTTEK
| Q4 25 | 78.3% | 18.2% | ||
| Q3 25 | 73.4% | 20.6% | ||
| Q2 25 | 77.1% | 18.4% | ||
| Q1 25 | 74.1% | 16.2% | ||
| Q4 24 | 76.2% | 15.6% | ||
| Q3 24 | 74.1% | 17.8% | ||
| Q2 24 | 77.8% | 16.6% | ||
| Q1 24 | 76.3% | 16.6% |
营业利润率BIIBTTEK
| Q4 25 | -2.5% | 11.6% | ||
| Q3 25 | 22.0% | 13.6% | ||
| Q2 25 | 28.1% | 12.0% | ||
| Q1 25 | 12.8% | 3.0% | ||
| Q4 24 | 11.9% | 1.6% | ||
| Q3 24 | 18.3% | 10.4% | ||
| Q2 24 | 28.3% | 9.6% | ||
| Q1 24 | 20.3% | 9.4% |
净利率BIIBTTEK
| Q4 25 | -2.1% | 8.7% | ||
| Q3 25 | 18.4% | 9.6% | ||
| Q2 25 | 24.0% | 8.3% | ||
| Q1 25 | 9.9% | 0.4% | ||
| Q4 24 | 10.9% | 0.1% | ||
| Q3 24 | 15.8% | 7.0% | ||
| Q2 24 | 23.7% | 6.4% | ||
| Q1 24 | 17.2% | 6.1% |
每股收益（稀释后）BIIBTTEK
| Q4 25 | $-0.35 | $0.40 | ||
| Q3 25 | $3.17 | $0.48 | ||
| Q2 25 | $4.33 | $0.43 | ||
| Q1 25 | $1.64 | $0.02 | ||
| Q4 24 | $1.82 | $0.00 | ||
| Q3 24 | $2.66 | $-3.18 | ||
| Q2 24 | $4.00 | $1.59 | ||
| Q1 24 | $2.70 | $1.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $269.4M |
| 总债务越低越好 | $6.3B | $837.1M |
| 股东权益账面价值 | $18.3B | $1.8B |
| 总资产 | $29.4B | $4.3B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资BIIBTTEK
| Q4 25 | — | $269.4M | ||
| Q3 25 | — | $167.5M | ||
| Q2 25 | — | $242.8M | ||
| Q1 25 | — | $179.4M | ||
| Q4 24 | — | $248.1M | ||
| Q3 24 | — | $232.7M | ||
| Q2 24 | — | $212.3M | ||
| Q1 24 | — | $210.3M |
总债务BIIBTTEK
| Q4 25 | $6.3B | $837.1M | ||
| Q3 25 | $6.3B | $766.4M | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | $1.0B | ||
| Q4 24 | $6.3B | $888.5M | ||
| Q3 24 | $4.5B | $812.6M | ||
| Q2 24 | $6.3B | $861.8M | ||
| Q1 24 | $6.3B | $951.0M |
股东权益BIIBTTEK
| Q4 25 | $18.3B | $1.8B | ||
| Q3 25 | $18.2B | $1.8B | ||
| Q2 25 | $17.6B | $1.7B | ||
| Q1 25 | $17.0B | $1.6B | ||
| Q4 24 | $16.7B | $1.7B | ||
| Q3 24 | $16.4B | $1.8B | ||
| Q2 24 | $15.9B | $1.7B | ||
| Q1 24 | $15.2B | $1.6B |
总资产BIIBTTEK
| Q4 25 | $29.4B | $4.3B | ||
| Q3 25 | $29.2B | $4.3B | ||
| Q2 25 | $28.3B | $4.4B | ||
| Q1 25 | $28.0B | $4.2B | ||
| Q4 24 | $28.0B | $4.2B | ||
| Q3 24 | $28.3B | $4.2B | ||
| Q2 24 | $26.8B | $4.1B | ||
| Q1 24 | $26.6B | $4.1B |
负债/权益比BIIBTTEK
| Q4 25 | 0.34× | 0.45× | ||
| Q3 25 | 0.35× | 0.43× | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | 0.64× | ||
| Q4 24 | 0.38× | 0.53× | ||
| Q3 24 | 0.28× | 0.44× | ||
| Q2 24 | 0.40× | 0.52× | ||
| Q1 24 | 0.41× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $72.3M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $68.1M |
| 自由现金流率自由现金流/营收 | 20.5% | 5.6% |
| 资本支出强度资本支出/营收 | 1.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 0.69× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $497.5M |
8季度趋势，按日历期对齐
经营现金流BIIBTTEK
| Q4 25 | $511.9M | $72.3M | ||
| Q3 25 | $1.3B | $100.8M | ||
| Q2 25 | $160.9M | $349.6M | ||
| Q1 25 | $259.3M | $-5.8M | ||
| Q4 24 | $760.9M | $13.1M | ||
| Q3 24 | $935.6M | $105.6M | ||
| Q2 24 | $625.8M | $140.9M | ||
| Q1 24 | $553.2M | $102.9M |
自由现金流BIIBTTEK
| Q4 25 | $468.0M | $68.1M | ||
| Q3 25 | $1.2B | $95.6M | ||
| Q2 25 | $134.3M | $345.6M | ||
| Q1 25 | $222.2M | $-11.8M | ||
| Q4 24 | $721.6M | $9.6M | ||
| Q3 24 | $900.6M | $98.8M | ||
| Q2 24 | $592.3M | $137.1M | ||
| Q1 24 | $507.3M | $98.9M |
自由现金流率BIIBTTEK
| Q4 25 | 20.5% | 5.6% | ||
| Q3 25 | 48.4% | 7.2% | ||
| Q2 25 | 5.1% | 25.2% | ||
| Q1 25 | 9.1% | -0.9% | ||
| Q4 24 | 29.4% | 0.7% | ||
| Q3 24 | 36.5% | 7.2% | ||
| Q2 24 | 24.0% | 10.2% | ||
| Q1 24 | 22.1% | 7.9% |
资本支出强度BIIBTTEK
| Q4 25 | 1.9% | 0.3% | ||
| Q3 25 | 1.8% | 0.4% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 1.5% | 0.4% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 1.4% | 0.5% | ||
| Q2 24 | 1.4% | 0.3% | ||
| Q1 24 | 2.0% | 0.3% |
现金转化率BIIBTTEK
| Q4 25 | — | 0.69× | ||
| Q3 25 | 2.73× | 0.79× | ||
| Q2 25 | 0.25× | 3.07× | ||
| Q1 25 | 1.08× | -1.08× | ||
| Q4 24 | 2.85× | 16.79× | ||
| Q3 24 | 2.41× | 1.10× | ||
| Q2 24 | 1.07× | 1.64× | ||
| Q1 24 | 1.41× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
TTEK
| Commercial International Services Group | $704.2M | 58% |
| Commercial | $225.4M | 19% |
| State And Local Government | $171.5M | 14% |
| Cost Plus | $95.1M | 8% |
| Related Party | $15.8M | 1% |
